(5E,8E,10E,14E,17E)-12-羟基二十-5,8,10,14,17-戊烯酸 | 74838-73-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (5E,8E,10E,14E,17E)-12-羟基二十-5,8,10,14,17-戊烯酸
• 英文名称: 12-Hydroxy-5,8,10,14,17-eicospentaenoic acid
• 英文别名: (5E,8E,10E,14E,17E)-12-hydroxyicosa-5,8,10,14,17-pentaenoic acid
• CAS: 74838-73-6
• 化学式: C₂₀H₃₀O₃
• 分子量: 318.4
• InChiKey: MCRJLMXYVFDXLS-ZRAJAZRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Differential diagnosis of liver disease
  申请人：The Regents of the University of California

  公开号：US10422786B2

  公开（公告）日：2019-09-24

  The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.

  本发明涉及肝脏疾病的基本无创诊断，特别是能够在早期阶段对此类疾病的进展进行干预。本发明进一步涉及使用血浆生物标志物来区分非酒精性脂肪性肝炎（NASH）与非酒精性脂肪肝（NAFL）和非酒精性脂肪肝（NAFLD）以及正常对照组。具体来说，本发明涉及利用血浆中游离二十烷酸和其他多不饱和脂肪酸（PUFA）代谢物水平来区分非酒精性脂肪性肝炎（NASH）和非酒精性脂肪性肝病（NAFL）以及非酒精性脂肪性肝病（NAFLD）正常对照组。
• DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE
  申请人：The Regents of the University of California

  公开号：EP3080613A1

  公开（公告）日：2016-10-19
• [EN] DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE<br/>[FR] DIAGNOSTIC DIFFÉRENTIEL DE MALADIE DU FOIE
  申请人：UNIV CALIFORNIA

  公开号：WO2015089102A1

  公开（公告）日：2015-06-18

  The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non- nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.